Diversify Advisory Services LLC Invests $1.82 Million in Gilead Sciences, Inc. $GILD

Diversify Advisory Services LLC bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund bought 13,919 shares of the biopharmaceutical company’s stock, valued at approximately $1,817,000.

Other hedge funds have also modified their holdings of the company. Strategic Investment Solutions Inc. IL acquired a new position in Gilead Sciences during the fourth quarter worth $25,000. Persistent Asset Partners Ltd purchased a new stake in shares of Gilead Sciences during the 2nd quarter worth $25,000. Vermillion & White Wealth Management Group LLC grew its stake in shares of Gilead Sciences by 71.4% during the 4th quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 85 shares during the period. Quattro Advisors LLC purchased a new position in shares of Gilead Sciences in the 4th quarter valued at about $26,000. Finally, Wealth Preservation Advisors LLC increased its holdings in shares of Gilead Sciences by 60.0% in the 4th quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 81 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: BMO Capital reaffirmed its Buy rating on Gilead, supporting the bullish view that the company’s recent momentum can continue. BMO Capital reaffirms Buy rating
• Positive Sentiment: Zacks Research raised estimates for third-quarter 2026 EPS to $1.93 from $1.84, fourth-quarter 2026 EPS to $2.14 from $2.07, and full-year 2027 EPS to $9.30 from $9.11. It also lifted estimates for parts of 2027, indicating improving expectations for near-term earnings. Gilead Sciences analyst estimates
• Positive Sentiment: Investors remain focused on Gilead’s expanding HIV portfolio. Biktarvy continues to anchor sales, while Yeztugo and additional pipeline programs could create new treatment and prevention opportunities. The company’s latest reported revenue also increased 10.6% year over year to $7.8 billion, exceeding expectations. Gilead’s expanding HIV portfolio
• Positive Sentiment: Gilead’s quarterly dividend of $0.82, equivalent to $3.28 annually, provides ongoing income support and reinforces its appeal to defensive and healthcare-focused investors.
• Neutral Sentiment: Zacks reduced estimates for first-quarter 2028 EPS to $2.14 from $2.21, second-quarter 2028 EPS to $2.27 from $2.33, and full-year 2028 EPS to $9.58 from $10.00. These cuts temper the otherwise positive near-term revisions and suggest some uncertainty about longer-term growth.
• Negative Sentiment: Chief Commercial Officer Johanna Mercier sold 28,000 shares, while CFO Andrew Dickinson sold 3,000 shares. Both transactions were made under pre-arranged Rule 10b5-1 plans, limiting their significance, but the sales may modestly weigh on sentiment.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on GILD. HSBC raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $133.00 to $155.00 in a report on Monday, July 6th. Weiss Ratings cut Gilead Sciences from a “buy (b-)” rating to a “hold (c-)” rating in a report on Tuesday, August 11th. Maxim Group raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 price objective for the company in a research note on Wednesday, May 20th. Rothschild & Co Redburn reduced their price objective on Gilead Sciences from $170.00 to $167.00 in a report on Monday, May 11th. Finally, Morgan Stanley decreased their price objective on shares of Gilead Sciences from $166.00 to $165.00 and set an “overweight” rating on the stock in a research report on Monday, July 27th. Twenty-four investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $158.04.

Gilead Sciences Stock Up 2.9%

GILD opened at $147.60 on Thursday. The firm has a market cap of $183.02 billion, a P/E ratio of -55.28 and a beta of 0.32. The business’s fifty day simple moving average is $131.21 and its 200 day simple moving average is $136.51. Gilead Sciences, Inc. has a 52 week low of $108.46 and a 52 week high of $157.29. The company has a quick ratio of 1.09, a current ratio of 1.27 and a debt-to-equity ratio of 2.03.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($7.25) by $0.50. The company had revenue of $7.80 billion for the quarter, compared to analyst estimates of $7.40 billion. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The firm’s quarterly revenue was up 10.6% on a year-over-year basis. During the same period in the prior year, the firm earned $2.01 EPS. As a group, equities research analysts anticipate that Gilead Sciences, Inc. will post -0.53 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th will be given a $0.82 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.2%. Gilead Sciences’s payout ratio is currently -122.85%.

Insider Activity

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $138.36, for a total transaction of $415,080.00. Following the completion of the transaction, the chief financial officer owned 165,646 shares of the company’s stock, valued at approximately $22,918,780.56. This represents a 1.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $137.64, for a total value of $3,853,920.00. Following the sale, the insider owned 118,234 shares of the company’s stock, valued at approximately $16,273,727.76. The trade was a 19.15% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 82,000 shares of company stock valued at $10,837,860 over the last quarter. Company insiders own 0.30% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.